| |  Online-Ressource |
|---|
| Verfasst von: | Hofmann, Lars Georg Emre [VerfasserIn]  |
|---|
| | Utikal, Jochen [VerfasserIn] |
|---|
| | Hassel, Jessica C. [VerfasserIn] |
|---|
| Titel: | Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy |
|---|
| Verf.angabe: | Lars Hofmann, Andrea Forschner, Carmen Loquai, Simone M. Goldinger, Lisa Zimmer, Selma Ugurel, Maria I. Schmidgen, Ralf Gutzmer, Jochen S. Utikal, Daniela Göppner, Jessica C. Hassel, Friedegund Meier, Julia K. Tietze, Ioannis Thomas, Carsten Weishaupt, Martin Leverkus, Renate Wahl, Ursula Dietrich, Claus Garbe, Michael C. Kirchberger, Thomas Eigentler, Carola Berking, Anja Gesierich, Angela M. Krackhardt, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie M. Heinzerling |
|---|
| E-Jahr: | 2016 |
|---|
| Jahr: | 13 April 2016 |
|---|
| Umfang: | 20 S. |
|---|
| Fussnoten: | Gesehen am 17.06.2019 |
|---|
| Titel Quelle: | Enthalten in: European journal of cancer |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1992 |
|---|
| Jahr Quelle: | 2016 |
|---|
| Band/Heft Quelle: | 60(2016), Seite 190-209 |
|---|
| ISSN Quelle: | 1879-0852 |
|---|
| Abstract: | Background - Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma as well as for other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tumours. As reported for ipilimumab, the anti-PD-1 antibodies pembrolizumab and nivolumab can induce immune-related adverse events (irAEs). These side-effects affect skin, gastrointestinal tract, liver, endocrine system and other organ systems. Since life-threatening and fatal irAEs have been reported, adequate diagnosis and management are essential. - Methods and findings - In total, 496 patients with metastatic melanoma from 15 skin cancer centers were treated with pembrolizumab or nivolumab; 242 side-effects were described in 138 patients. In 116 of the 138 patients, side-effects affected the skin, gastrointestinal tract, liver, endocrine, and renal system. Rare side-effects included diabetes mellitus, lichen planus, and pancreas insufficiency due to pancreatitis. - Conclusion - Anti-PD1 antibodies can induce a plethora of irAEs. The knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity. |
|---|
| DOI: | doi:10.1016/j.ejca.2016.02.025 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.ejca.2016.02.025 |
|---|
| | Volltext: http://www.sciencedirect.com/science/article/pii/S0959804916001519 |
|---|
| | DOI: https://doi.org/10.1016/j.ejca.2016.02.025 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Adverse event |
|---|
| | Anti-PD-1 |
|---|
| | Checkpoint inhibitors |
|---|
| | Immune-related |
|---|
| | Nivolumab |
|---|
| | Pembrolizumab |
|---|
| | Side-effect |
|---|
| | Tolerability |
|---|
| | Toxicity |
|---|
| K10plus-PPN: | 1667552570 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy / Hofmann, Lars Georg Emre [VerfasserIn]; 13 April 2016 (Online-Ressource)
